|Bid||0.0000 x 1200|
|Ask||0.0000 x 800|
|Day's Range||4.7200 - 5.0532|
|52 Week Range||4.6200 - 10.0000|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.25|
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced several preclinical data presentations, including an oral presentation, will be delivered at the 24th Annual American Society of Gene and Cell Therapy (ASGCT) Virtual Meeting being held May 11-14, 2021. In an oral presentation, Dr. Jing Liao, Associate Director at LogicBio, will discuss results from preclinical studies of the adeno-associated virus (AAV) sL65, the first AAV capsid produced from LogicBio's sAAVyTM platform, for the potential treatment of serious diseases of the liver. Results show high potency in a humanized mouse model and in non-human primates compared to widely used benchmark liver targeting capsids. The sL65 capsid also shows high production yields in suspension HEK293 cells and in bioreactors.
LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia (MMA) caused by a deficiency of the mitochondrial enzyme methylmalonyl-CoA mutase (MMUT). The study results were recently highlighted in a poster presentation at the American College of Medical Genetic and Genomics (ACMG) Annual Clinical Genetics Meeting.
CANbridge Pharmaceuticals Inc has entered into a strategic collaboration and licensing agreement with LogicBio Therapeutics Inc (NASDAQ: LOGC) to develop, manufacture and commercialize gene therapy candidates for treatments for Fabry and Pompe diseases. The candidates will be based on LogicBio's adeno-associated virus (AAV) sL65, the first capsid produced from the LogicBio sAAVy platform. The agreement also includes options for the development of AAV sL65-based treatments for two additional indications. CANbridge is also granted an option to an exclusive license for LB-001, an investigational in-vivo gene-editing technology based on the GeneRide platform to treat methylmalonic acidemia (MMA) in Greater China (China, Taiwan, Hong Kong, and Macau). Under the terms of the agreement, LogicBio will receive an upfront payment of $10 million for Fabry and Pompe disease candidates. Upon exercising the option for LB-001, CANbridge would assume responsibility and costs for all future development. The agreement also milestone payments for up to $581 million and up to double-digit royalties on net sales. Additionally, LogicBio signed a research collaboration and exclusive option agreement with Daiichi Sankyo (OTCMKTS: DSKYF). The companies will collaborate on developing treatments for two undisclosed indications based on GeneRide, LogicBio's proprietary gene insertion platform. The financial terms of the collaboration are not disclosed. Price Action: LOGC shares are up 0.17% at $6.011 during the market session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaObsEva Starts Long-term Follow-Up Study To Evaluate Bone Mineral Density After Yselty TreatmentMerck Teams Up With Five Indian Generic Players To Expand COVID-19 Drug Access, Production© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.